Allergan Stymies Generic Glaucoma Med In Patent Trial

Law360, New York (January 14, 2014, 7:56 PM EST) -- Allergan Inc. halted four competing drugmakers' attempts to produce generic versions of its glaucoma drug Lumigan on Monday, when a Texas federal judge ruled that their proposed products would infringe five patents for the brand-name drug.

Following a four-day bench trial, U.S. District Judge Michael H. Schneider entered final judgment in favor of the Irvine, Calif.-based pharmaceuticals giant, finding that the formulas for generics being developed by Sandoz Inc., Lupin Pharmaceuticals Inc., Hi-Tech Pharmacal Co. Inc. and Watson Laboratories Inc. violated the patents, and that any...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.